Eleanor M. Perfetto, PhD, MS

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone.

Placing formulary restrictions on brand name drugs shifts use toward generics, lowers the cost per prescription fill, and has minimal impact on overall adherence for antidiabetes, antihyperlipidemia, and antihypertension medications among low-income subsidy recipients in Medicare Part D plans.

A reaction to Institute for Clinical and Economic Review's value assessment framework by Eleanor M. Perfetto, PhD, MS, of The National Health Council.